Medical device manufacturers must embed cybersecurity into pre-market and post-market device design to comply with the FDA's Federal Food, Drug, and Cosmetic Act Section 524B, enforced by the U.S. Food and Drug Administration (FDA), addressing the sector-specific risk of patient safety incidents and network compromise from connected medical devices. This requirement applies to any manufacturer submitting a premarket submission for a device with electronic software, including those integrating artificial intelligence, and demands continuous post-market vulnerability management and a robust Software Bill of Materials (SBOM).
The Evolving Threat Landscape for Medical Device Manufacturers in the USA
The US healthcare sector remains a primary target for cyber adversaries, with the Ponemon Institute's 2024 Cost of a Data Breach study reporting healthcare breaches reached an average of $10.93 million per incident, the highest of any industry for the fourteenth consecutive year. Medical devices present an expanded attack surface, often running legacy operating systems, communicating over unsecured networks, and lacking native security controls. Ransomware groups increasingly target hospitals by compromising infusion pumps, imaging systems, and hospital IoT devices, creating both clinical disruption and data theft. The US Cybersecurity and Infrastructure Security Agency (CISA) regularly alerts on vulnerabilities in medical devices, from pacemaker communication protocols to radiology software APIs, underscoring that device security is now inseparable from patient safety.
For manufacturers, the risk extends beyond direct attack to regulatory liability. The FDA's FDA medical device cybersecurity guidance mandates that cybersecurity be treated as a design input, not an afterthought. Meanwhile, the Health Insurance Portability and Accountability Act (HIPAA) Security Rule (45 CFR §164.312) requires covered entities and business associates to ensure the integrity of electronic protected health information (ePHI). Failure to secure devices that generate, store, or transmit ePHI exposes manufacturers to potential enforcement action from the HHS Office for Civil Rights (OCR) and the FDA's Center for Devices and Radiological Health (CDRH).
The US government's National Cybersecurity Strategy, coupled with CISA's Binding Operational Directives for critical infrastructure, further pressures manufacturers to adopt secure-by-design principles, threat modeling (e.g., STRIDE), and ongoing penetration testing. Manufacturers shipping devices to US hospitals must also consider state-level breach notification laws (the 50-state patchwork), which require rapid reporting if patient data is compromised via a device vulnerability.
What FDA Section 524B Requires: Key Compliance Obligations for Manufacturers
Section 524B of the Federal Food, Drug, and Cosmetic Act, as codified by the 2023 final rule, creates binding cybersecurity requirements for medical devices. The FDA’s healthcare cybersecurity framework demands that manufacturers demonstrate "reasonable assurance" that their devices are secure. For US-region manufacturers, the core obligations include:
- Submission of a Software Bill of Materials (SBOM): Manufacturers must provide a detailed SBOM with every premarket submission, listing all commercial, open-source, and off-the-shelf software components, including version numbers and known vulnerabilities. The SBOM enables hospital security teams to monitor for vulnerabilities throughout the device's life.
- Post-market Cybersecurity Management: Manufacturers must establish a process for identifying, assessing, and remediating vulnerabilities on an ongoing basis, including coordinating disclosure with CISA and the FDA. The plan must address continued safety and effectiveness after a vulnerability is discovered.
- Security Design Inputs: Devices must be designed with cybersecurity controls including authentication, encryption, secure boot, and least-privilege access. Threat modeling and risk analysis (e.g., based on NIST CSF 2.0 or ISO 14971) must be documented as part of the design history file.
- Timely Patch Capability: Devices must support the ability to receive and apply security patches. Manufacturers must also ensure that patches do not compromise clinical safety.
Failure to comply with Section 524B can result in a refusal to accept the premarket submission, a clinical hold, or even a misbranding action under the FD&C Act. For manufacturers already on the market, non-compliance with post-market obligations can lead to a recall or corrective action ordered by the FDA.
Key Compliance Warning: The FDA has signaled that recall actions may be taken for devices that cannot be patched or lack an SBOM. In 2024, the FDA issued safety communications for multiple device families due to missing security controls, emphasizing that cybersecurity is now a patient safety imperative.
The Hardest Controls for Medical Device Manufacturers
While the letter of Section 524B is clear, implementation presents unique challenges distinct from conventional IT security. Our team at CyberSilo observes that manufacturers struggle most with the following areas:
- Embedding Security into Legacy Device Design: Many devices have development lifecycles spanning 5-10 years. Retrofitting secure boot, encryption, and authentication into existing hardware and firmware is technically complex and costly. Manufacturers must often redesign hardware for next-generation products while maintaining backward compatibility.
- SBOM Generation and Management: Maintaining an accurate, up-to-date SBOM across multiple product lines is a data management challenge. Vendors often source components from third-party suppliers who may not provide detailed vulnerability data, creating supply chain risk.
- Post-market Vulnerability Coordination: Coordinating disclosure with CISA, the FDA, and customers while managing the risk of a zero-day exploit requires a mature vulnerability management program. The pressure to quickly issue patches must be balanced against the need for FDA re-clearance (a 510(k) supplement may be required if the change is significant).
- Compliance Across Multiple US Frameworks: Manufacturers often must simultaneously comply with HIPAA (if handling ePHI), NIST SP 800-53 (for federal customers), and the FDA's specific cybersecurity guidance. This creates a complex overlay of controls, with overlapping but not identical requirements.
Strengthen Your FDA 524B Compliance Posture for Connected Medical Devices
Our team helps medical device manufacturers automate SBOM generation, threat modeling, and compliance reporting to meet FDA, CISA, and HIPAA requirements. Reduce compliance overhead and accelerate time-to-market.
How CyberSilo's Compliance Automation Addresses FDA 524B for Manufacturers
CyberSilo's Compliance Standards Automation solution is designed to streamline the specific compliance obligations medical device manufacturers face under FDA 524B. Our platform integrates across the full device lifecycle, from design to post-market monitoring:
- SBOM Automation: Our platform automatically generates and maintains SBOMs from your build pipeline, matching components to the National Vulnerability Database (NVD) and CISA's Known Exploited Vulnerabilities (KEV) catalog. The SBOM is formatted for FDA submission and includes all required metadata.
- Post-market Vulnerability Scanning: Continuous monitoring of your device's software supply chain and known vulnerabilities. The system prioritizes vulnerabilities by CVSS score and exploitability, then generates a remediation plan aligned with FDA's post-market guidance.
- Controls Mapping to FDA, HIPAA, and NIST: Our platform maps your existing security controls (e.g., authentication, encryption, audit logging) to the specific requirements of Section 524B, the HIPAA Security Rule, and NIST SP 800-53, producing a single gap analysis. This reduces the manual effort of preparing a premarket submission (e.g., a 510(k) with cybersecurity documentation).
- Policy and Evidence Repository: Centralized storage for your design history, test results, and vulnerability disclosures, enabling rapid response to FDA inquiries or audit requests.
For US cybersecurity compliance, CyberSilo's platform is validated by multiple US healthcare organizations and integrates with existing DevSecOps workflows, ensuring security is built in, not bolted on.
Checklist: Essential Documentation for FDA 524B Premarket Submission
Before submitting any device with electronic software to the FDA, confirm your submission includes the following elements. This checklist aligns with the CDRH's final guidance on cybersecurity in medical devices.
Automate Your FDA 524B Documentation and Gap Analysis
Let our compliance experts help you build a complete submission-ready security package. Reduce manual work and avoid submission delays.
Post-market Vulnerability Management: A Structured Workflow for Manufacturers
Once a device is on the market, manufacturers must maintain a continuous vulnerability management process. The following workflow aligns with FDA, CISA, and OCR expectations for healthcare cybersecurity:
Vulnerability Identification and Prioritization
Monitor the NVD, CISA KEV, and vulnerability databases (e.g., via automated feeds from our Compliance Automation platform). Also monitor advisories from third-party component vendors. Use CVSS 3.1 and exploitability to prioritize—any vulnerability with a known exploit or active use in healthcare environments should be prioritized as critical.
Risk Assessment and Safety Impact Analysis
For each vulnerability, conduct a patient safety risk assessment. Will exploitation cause clinical harm? For example, a vulnerability in an implantable device that allows unauthenticated communication is a direct safety risk and requires immediate disclosure. Document the risk acceptance if a patch cannot be immediately deployed.
Coordinated Disclosure to CISA and the FDA
If the vulnerability poses a patient safety risk, report to CISA (via the MS-ISAC or direct) and the FDA within 72 hours of confirmation under the FDA's voluntary reporting framework. Follow the 2023 CISA/FDA joint guidance for medical device vulnerability disclosure.
Patch Development, Testing, and Deployment
Develop a security patch. Test it for both security efficacy and clinical safety (verifying it does not affect device performance). If the change is significant (e.g., alters the device's essential performance), submit a 510(k) supplement to the FDA before deploying. Deploy the patch to customers with clear instructions.
Post-patch Monitoring and Documentation
After patching, update the SBOM, document the vulnerability lifecycle, and continue monitoring for any residual issues. Maintain a record for at least the device's expected lifespan (typically 5-10 years) for potential OCR or FDA audit.
Executive Insight: "One of the hardest challenges for device makers is balancing the speed of patching with the need for FDA re-clearance. Our platform helps you maintain a 'safe and effective' justification quickly, allowing you to move faster without compromising compliance," says our lead regulatory advisor.
Our Conclusion & Recommendation
Medical device cybersecurity is now a regulatory and patient safety reality under FDA Section 524B. Manufacturers that fail to build security into device design and post-market processes face submission delays, recalls, and increasing liability under US law. CyberSilo's Compliance Standards Automation directly addresses the complexity of SBOM management, vulnerability coordination, and multi-framework compliance (FDA, HIPAA, NIST), reducing the time and risk of bringing secure devices to market.
For any manufacturer submitting a premarket device in 2025, our recommendation is to audit your current design process against the checklist above and contact our security team for a gap analysis tailored to your product pipeline.
Ready to Align Your Device Pipeline with FDA 524B?
Our industry specialists, based in the US, can help you automate submission documentation and build a post-market monitoring process that satisfies the FDA and CISA.
